The TANGO trial demonstrated the efficacy of lamivudine plus dolutegravir in virologically suppressed patients without previous virological failures (VF). In this dataset from clinical practice investigating the impact of past NRTI resistance on this strategy, the combination of M184V/I plus at least one TAM significantly increased the risk of VF.
NRTI resistance mutations predict virological failure in HIV-positive patients during lamivudine plus dolutegravir maintenance therapy in clinical practice / A. Borghetti, A. Giacomelli, V. Borghi, A. Ciccullo, A. Dusina, M. Fabbiani, S. Rusconi, M. Zazzi, C. Mussini, S. Di Giambenedetto. - In: OPEN FORUM INFECTIOUS DISEASES. - ISSN 2328-8957. - (2021). [Epub ahead of print] [10.1093/ofid/ofab103]
NRTI resistance mutations predict virological failure in HIV-positive patients during lamivudine plus dolutegravir maintenance therapy in clinical practice
A. GiacomelliSecondo
;S. Rusconi;
2021
Abstract
The TANGO trial demonstrated the efficacy of lamivudine plus dolutegravir in virologically suppressed patients without previous virological failures (VF). In this dataset from clinical practice investigating the impact of past NRTI resistance on this strategy, the combination of M184V/I plus at least one TAM significantly increased the risk of VF.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Borghetti et al NRTI DTG.pdf
accesso aperto
Tipologia:
Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione
598.98 kB
Formato
Adobe PDF
|
598.98 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
